PRU:LSEPrudential plc Analysis
Data as of 2026-05-27 - not real-time
£1,113.57
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Prudential plc is trading at £1,113.57, comfortably above its 20‑day SMA of £1,132.80 but still below the 50‑day and 200‑day averages, indicating a modest short‑term pull‑back within a longer‑term uptrend. The RSI of 45.9 sits near the neutral zone, while the MACD shows a bearish crossover (histogram –3.94), and volume is trending lower, suggesting cautious momentum ahead of the next move toward the £1,204 resistance level. Market sentiment is at an “Extreme Greed” level (91.13 on the Fear & Greed Index), and volatility remains elevated at ~28% over the past 30 days, which could amplify price swings.
Fundamentally, PRU is markedly undervalued with a trailing P/E of 9.77 versus the industry average of 16.58, and a DCF‑derived fair value of £3,043 implies roughly 27% upside. Strong operating margins (45% operating, 27% profit), robust ROE of 20.6%, low debt‑to‑equity (28.3) and a modest dividend yield of 1.75% with a 15% payout ratio point to sustainable earnings and cash flow. The beta of 0.72 signals lower market sensitivity, and the company’s diversified Asian‑African footprint adds growth potential while keeping overall risk moderate.
Fundamentally, PRU is markedly undervalued with a trailing P/E of 9.77 versus the industry average of 16.58, and a DCF‑derived fair value of £3,043 implies roughly 27% upside. Strong operating margins (45% operating, 27% profit), robust ROE of 20.6%, low debt‑to‑equity (28.3) and a modest dividend yield of 1.75% with a 15% payout ratio point to sustainable earnings and cash flow. The beta of 0.72 signals lower market sensitivity, and the company’s diversified Asian‑African footprint adds growth potential while keeping overall risk moderate.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Bearish MACD crossover and decreasing volume
- Price near support at £1,053
- Neutral RSI indicating limited upside in the near term
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation gap (P/E 9.8 vs industry 16.6)
- DCF fair value suggesting ~27% upside
- Strong operating and profit margins
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustained dividend with low payout ratio
- Diversified growth exposure in Asia and Africa
- Low beta and solid balance sheet supporting resilience
Key Metrics & Analysis
Financial Health
Revenue Growth18.80%
Profit Margin27.57%
P/E Ratio9.8
ROE20.58%
ROA1.89%
Debt/Equity28.25
P/B Ratio1.9
Op. Cash Flow£2.4B
Free Cash Flow£2.8B
Industry P/E16.6
Technical Analysis
TrendBullish
RSI45.9
Support£1,053.00
Resistance£1,204.00
MA 20£1,132.80
MA 50£1,108.55
MA 200£1,086.73
MACDBearish
VolumeDecreasing
Fear & Greed Index91.13
Valuation
Fair Value£3,043.14
Target Price£1,410.44
Upside/Downside26.66%
GradeUndervalued
TypeBlend
Dividend Yield1.75%
Risk Assessment
Beta0.72
Volatility28.26%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.